RU2018136782A - Производные тритерпиноидов - Google Patents
Производные тритерпиноидов Download PDFInfo
- Publication number
- RU2018136782A RU2018136782A RU2018136782A RU2018136782A RU2018136782A RU 2018136782 A RU2018136782 A RU 2018136782A RU 2018136782 A RU2018136782 A RU 2018136782A RU 2018136782 A RU2018136782 A RU 2018136782A RU 2018136782 A RU2018136782 A RU 2018136782A
- Authority
- RU
- Russia
- Prior art keywords
- triterpene
- carbon
- activation
- derivative
- pathological condition
- Prior art date
Links
- 150000003648 triterpenes Chemical class 0.000 claims 21
- 230000004913 activation Effects 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 230000001575 pathological effect Effects 0.000 claims 16
- 230000037361 pathway Effects 0.000 claims 16
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 10
- 206010012601 diabetes mellitus Diseases 0.000 claims 8
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 6
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 4
- 200000000007 Arterial disease Diseases 0.000 claims 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 4
- 208000033626 Renal failure acute Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 206010052428 Wound Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 201000011040 acute kidney failure Diseases 0.000 claims 4
- 206010069351 acute lung injury Diseases 0.000 claims 4
- 208000012998 acute renal failure Diseases 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 206010008129 cerebral palsy Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 230000008736 traumatic injury Effects 0.000 claims 4
- 150000002923 oximes Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000007857 hydrazones Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16193684.4 | 2016-10-13 | ||
| EP16193684 | 2016-10-13 | ||
| PCT/EP2017/075042 WO2018069086A1 (en) | 2016-10-13 | 2017-10-03 | Hydroxamate triterpenoid derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018136782A true RU2018136782A (ru) | 2020-04-20 |
| RU2018136782A3 RU2018136782A3 (https=) | 2020-04-20 |
Family
ID=57136723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018136782A RU2018136782A (ru) | 2016-10-13 | 2017-10-03 | Производные тритерпиноидов |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10766855B2 (https=) |
| EP (1) | EP3365351B1 (https=) |
| JP (1) | JP6598224B2 (https=) |
| KR (1) | KR102038930B1 (https=) |
| CN (1) | CN108368150B (https=) |
| AU (1) | AU2017341257B2 (https=) |
| BR (1) | BR112018068996A2 (https=) |
| CA (1) | CA3020387C (https=) |
| ES (1) | ES2774198T3 (https=) |
| HK (1) | HK1254200A1 (https=) |
| IL (1) | IL259391B (https=) |
| MX (2) | MX364919B (https=) |
| RU (1) | RU2018136782A (https=) |
| WO (1) | WO2018069086A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020157494A1 (en) * | 2019-01-30 | 2020-08-06 | Rothamsted Research Ltd | Cylodimer of dehydrosalicortin and derivatives thereof isolated from plant of the genus salix for use in cancer therapy |
| CN114805469A (zh) * | 2021-01-27 | 2022-07-29 | 中国科学院上海药物研究所 | 含吡唑的白桦脂酸类衍生物，其制备方法及用途 |
| CN117567544A (zh) * | 2021-04-27 | 2024-02-20 | 中国医学科学院药物研究所 | 一类具有α,β-不饱和酮结构五环三萜类化合物在预防和治疗神经退行性疾病中的用途 |
| WO2024145502A1 (en) * | 2022-12-29 | 2024-07-04 | The Board Of Regents Of The University Of Texas System | Synthetic triterpenoids and compositions thereof in weight management, skeletal muscle function, and appetite suppression |
| CN119504913B (zh) * | 2024-11-18 | 2025-09-26 | 南京中医药大学 | 一类五环三萜衍生物及其医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002322068A (ja) * | 2001-02-26 | 2002-11-08 | Japan Science & Technology Corp | 血管再生促進剤 |
| KR100821649B1 (ko) * | 2006-01-24 | 2008-04-11 | 서울시립대학교 산학협력단 | 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제 |
| CN101367861A (zh) * | 2007-08-15 | 2009-02-18 | 中国药科大学 | 2-羟基-3-脱氧五环三萜类化合物及其衍生物、其制备方法及用途 |
| PL2252283T3 (pl) * | 2008-01-11 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby |
| WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| US20100144688A1 (en) * | 2008-12-10 | 2010-06-10 | Advanced Life Sciences, Inc. | 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids |
| KR101811462B1 (ko) * | 2010-01-11 | 2018-01-25 | 피닉스 바이오테크놀러지 인코포레이티드. | 협죽도 추출물을 포함하는 신경질환 치료용 조성물 |
| CN102180939B (zh) | 2011-03-30 | 2013-02-20 | 沈阳化工大学 | 一种抗肿瘤活性的熊果酸化学修饰物及其制备方法 |
| US8324264B1 (en) * | 2011-07-22 | 2012-12-04 | Sequoia Sciences, Inc. | Inhibitors of bacterial biofilms and related methods |
| CN102499925B (zh) * | 2011-10-21 | 2015-11-11 | 上海中医药大学 | 一种中性粒细胞弹性蛋白酶抑制剂 |
-
2017
- 2017-10-03 EP EP17790966.0A patent/EP3365351B1/en active Active
- 2017-10-03 WO PCT/EP2017/075042 patent/WO2018069086A1/en not_active Ceased
- 2017-10-03 US US16/099,800 patent/US10766855B2/en active Active
- 2017-10-03 KR KR1020187028923A patent/KR102038930B1/ko not_active Expired - Fee Related
- 2017-10-03 CN CN201780004882.0A patent/CN108368150B/zh not_active Expired - Fee Related
- 2017-10-03 CA CA3020387A patent/CA3020387C/en active Active
- 2017-10-03 MX MX2018006429A patent/MX364919B/es active IP Right Grant
- 2017-10-03 BR BR112018068996A patent/BR112018068996A2/pt not_active Application Discontinuation
- 2017-10-03 ES ES17790966T patent/ES2774198T3/es active Active
- 2017-10-03 JP JP2018524188A patent/JP6598224B2/ja active Active
- 2017-10-03 HK HK18113340.0A patent/HK1254200A1/zh unknown
- 2017-10-03 AU AU2017341257A patent/AU2017341257B2/en active Active
- 2017-10-03 RU RU2018136782A patent/RU2018136782A/ru not_active Application Discontinuation
-
2018
- 2018-05-15 IL IL25939118A patent/IL259391B/en active IP Right Grant
- 2018-05-24 MX MX2019005448A patent/MX2019005448A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102038930B1 (ko) | 2019-11-05 |
| AU2017341257A1 (en) | 2018-11-01 |
| AU2017341257B2 (en) | 2019-08-08 |
| IL259391A (en) | 2018-07-31 |
| MX2019005448A (es) | 2019-07-04 |
| CN108368150A (zh) | 2018-08-03 |
| US10766855B2 (en) | 2020-09-08 |
| WO2018069086A1 (en) | 2018-04-19 |
| MX2018006429A (es) | 2018-09-27 |
| CA3020387C (en) | 2020-07-28 |
| IL259391B (en) | 2019-10-31 |
| RU2018136782A3 (https=) | 2020-04-20 |
| BR112018068996A2 (pt) | 2019-01-22 |
| KR20180117700A (ko) | 2018-10-29 |
| ES2774198T3 (es) | 2020-07-17 |
| EP3365351B1 (en) | 2019-12-04 |
| EP3365351A1 (en) | 2018-08-29 |
| CN108368150B (zh) | 2022-02-25 |
| US20190367447A1 (en) | 2019-12-05 |
| CA3020387A1 (en) | 2018-04-19 |
| JP6598224B2 (ja) | 2019-10-30 |
| MX364919B (es) | 2019-05-13 |
| JP2019519464A (ja) | 2019-07-11 |
| HK1254200A1 (zh) | 2019-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018136782A (ru) | Производные тритерпиноидов | |
| DK2959900T3 (en) | CONNECTION TO TREATMENT OF CANCER | |
| JP2019519464A5 (https=) | ||
| WO2008080986A1 (en) | Furan derivatives, method of synthesis and uses thereof | |
| WO2021011592A1 (en) | Compounds as nlrp3 inflammasome inhibitors and compositions and uses thereof | |
| NO143796B (no) | Analogifremgangsmaate til fremstilling av terapeutisk virksomme piperazinyliminorifamyciner | |
| US10344001B2 (en) | Azolylacryloyl derivatives as therapeutic agents for sickle cell disease | |
| US10093628B2 (en) | Competitive PPAR-gamma antagonists | |
| RU2259361C2 (ru) | Профилактическое или терапевтическое средство и фармацевтическая композиция, содержащая гетероциклическое соединение | |
| AU2021221120A1 (en) | Compounds, compositions, and methods for protein degradation | |
| CN112118837B (zh) | 抗菌剂：o-烷基氘化派洛宁 | |
| JP6619349B2 (ja) | 新規なカンナビゲロール誘導体 | |
| CA3196267A1 (en) | Compositions and methods for treating neuronal disorders with cannabinoids | |
| WO2014192023A1 (en) | Novel compounds suitable for the treatment of dyslipidemia | |
| RU2473550C1 (ru) | 16-(1,2,4-оксадиазол-3-ил)-15,16-эпоксилабданоиды, обладающие цитотоксической активностью по отношению к опухолевым клеткам человека | |
| AU2007314085B2 (en) | Dithiole compounds as COX inhibitors | |
| RU2479582C1 (ru) | 6-гидроксинафтохиноны лабданового типа, обладающие цитотоксической активностью по отношению к опухолевым клеткам человека | |
| EP3413883A1 (en) | Novel class of compounds for the treatment of cardiovascular disease | |
| US20110257145A1 (en) | Method of treating neurological diseases | |
| CN114828958A (zh) | 含环烷基的羧酸和其用途 | |
| WO2018209062A1 (en) | Prodrug derivatives of protein kinase c modulators | |
| HK1229783A1 (en) | Novel cannabigerol derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200805 |